Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Gibson, J. P.
Right arrow Articles by Newberne, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gibson, J. P.
Right arrow Articles by Newberne, J. W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal Article

Chronic Toxicity Studies with Vigabatrin, A GABA-Transaminase Inhibitor

John P. Gibson

Merrell Dow Research Institute, Merrell Dow Pharmaceuticals Inc., Cincinnati, Ohio 45215

John T. Yarrington

Merrell Dow Research Institute, Merrell Dow Pharmaceuticals Inc., Cincinnati, Ohio 45215

David E. Loudy

Merrell Dow Research Institute, Merrell Dow Pharmaceuticals Inc., Cincinnati, Ohio 45215

Clifford G. Gerbig

Merrell Dow Research Institute, Merrell Dow Pharmaceuticals Inc., Cincinnati, Ohio 45215

Gail H. Hurst

Merrell Dow Research Institute, Merrell Dow Pharmaceuticals Inc., Cincinnati, Ohio 45215

James W. Newberne

Merrell Dow Research Institute, Merrell Dow Pharmaceuticals Inc., Cincinnati, Ohio 45215

The GABA-transaminase inhibitor, vigabatrin, has been shown to have a rather low degree of acute toxicity in several animal species. Oral administration of the drug at 1,000 mg/kg/day for 2-4 weeks caused decreased food consumption and weight loss with resultant prostration and death in both rats and dogs. Dosages of 200 mg/kg/day were tolerated for a year without clinical signs in dogs, although rats suffered reduced weight gains and convulsions after 3-4 months when given the drug in the diet. The convulsions continued to occur frequently throughout the one-yr study, but abated 3-4 months after cessation of treatment. The only consistent histopathologic evidence of toxicity in rats and dogs has been the finding of intramyelinic edema (microvacuolation) in the brain, most notably in certain areas of white matter (cerebellum, reticular formation and optic tract in rats and columns of fornix and optic tract in dogs). No lesions were found in the spinal cord or peripheral nervous system. It took several weeks for the microvacuolation to develop, even at high dosages, but it did not continue to progress thereafter, even though a slight effect was noted at dosages as low as 30-50 mg/kg/day after one yr of treatment. The intramyelinic edemia disappeared within a few weeks after treatment was withdrawn. No residual effects were observed in dogs, whereas rats exhibited swollen axons and microscopic mineralized bodies in the cerebellum. Monkeys exhibited no adverse clinical effects except for occasional loose stools at 300 mg/kg/day. After 16 months of oral treatment at 300 mg/kg/day any suggestion of intramyelinic edema was considered to be equivocal, and there was no evidence of any effect in the 50 or 100 mg/kg/day monkeys after 6 yr of treatment. Higher doses caused chronic diarrhea, thus limiting the dosage in this species. Vigabatrin was shown to be well absorbed in rat, dog and man, whereas dose-limited absorption occurred in the monkey. Metabolism is practically nil in all 4 species and the primary elimination pathway is by glomerular filtration. Because vigabatrin is an irreversible inhibitor of GABA-transaminase and the enzyme has a slow turnover rate, plasma levels of the drug are not indicative of its pharmacologic activity. For this reason cerebrospinal fluid levels of GABA and vigabatrin were evaluated, with considerable species differences being noted. The significance of these differences in relation to the differences in toxic response is discussed.

Key Words: {gamma}-vinyl GABA • GVG • intramyelinic edema • rat • dog • monkey

  • 1. Aleu FP, Katzman R, and Terry RD (1963). Fine structure and electrolyte analyses of cerebral edema induced by alkyl tin intoxication. J. Neuropathol. Exp. Neurol. 22: 403–413.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 2. Ben-Menachcm E, Persson LI, Schechter PJ, Haegele KD, Huebert N, Hardenberg J, Dahlgren L, and Mumford JP (1989). The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Brit. J. Gin. Pharmacol. 27(Suppl. 1): 79S–85S.
  • 3. Bohlen P, Huot S, and Palfreyman MG (1979). The relationship between GABA concentrations in brain and cerebrospinal fluid. Brain Res. 167: 297–305.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 4. Browne TR, Mattson RH, Penry JK, Smith DB, Treiman DM, Wilder BJ, Ben-Menachem E, Napoliello MJ, Sherry KM, and Szabo GK (1987). Vigabatrin for refractory complex partial seizures; multicenter single-blind study with long-term follow-up. Neurology 37: 184–189.[Abstract/Free Full Text]
  • 5. Butler WH, Ford GP, and Newbcrne JW (1987). A study of the effects of vigabatrin on the central nervous system and retina of Sprague-Dawley and Lister-Hooded rats. Toxicol. Pathol. 15: 143–148.[Web of Science][Medline] [Order article via Infotrieve]
  • 6. Fowler L (1973). Analysis of the major amino acids of rat brain after in vivo inhibition of transaminase by ethanolamine-o-sulphate. J. Neurochem. 21: 437–440.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 7. Graham DG Department of Pathology, Duke University Medical Center, Durham, NC 27710. (Personal communication.)
  • 8. Gram L, Klosterkov P, and Dam M (1985). Gammavinyl GABA: A double-blind placebo-controlled trial in partial epilepsy. Ann. Neurol. 17: 262–266.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 9. Grove J, Palfreyman MG, and Schechter PJ (1983). Cerebrospinal fluid GABA as an index of brain GABA activity. Clin. Neuropharmacol. 6: 223–229.[Web of Science][Medline] [Order article via Infotrieve]
  • 10. Grove J, Scnechter PJ, Tell G, Koch-Weser J, Sjoerdsma A, Warter JM, Marescaux C, and Rumbach L (1981). Increased {gamma}-amino-butyric acid (GABA), homocarnosine and β-alanine in cerebrospinal fluid of patients treated with {gamma}-vinyl GABA (4-amino-hex-5-enoicacid). Life Sci. 28: 2431–2439.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 11. Hammond EJ and Wilder BJ (1985). Minireview: Gamma-vinyl GABA. Gen. Pharmacol. 16: 441–447.[Web of Science][Medline] [Order article via Infotrieve]
  • 12. Hauw J-J, Trottier S, Boutry J-M, Sun P, Sazdovitch V, and Duyckaerts C (1988). The neuropathology of vigabatrin. Brit. J. Gin. Practice 42(Suppl. 61): 10–13.
  • 13. Howard JL, White HL, Cooper BR, and Rohrbach K.W (1982). Control of body weight by manipulation of brain gamma-amino-butyric acid (GABA) levels. Fed. Proc. 41: 1060, Abst. 4617.
  • 14. John RA, Rimmer EM, Williams J, Cole G, Fowler LJ, and Richens A (1987). Micro-vacuolation in rat brains after long term administration of GABA-transaminase inhibitors: Comparison of effects of eth-anolamine-O-sulphatc and vigabatrin. Biochem. Pharmacol. 36: 1467–1473.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 15. Jung MJ, Lippert B, Metcalf BW, Bohlen P, and Schechter PJ (1977). {gamma}-Vinyl GABA (4-amino-hex-5-enoic acid). A new selective irreversible inhibitor of GABA-T. Effects on brain GABA metabolism in mice. J. Neurochem. 29: 797–802.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 16. Jung MJ (1980). Design, biochemistry and pharmacology of enzyme-activated irreversible inhibitors of GABA. In: Enzyme Inhibitors, U Brodbeck (ed). Verlag Chemie, Weinheim, pp. 85–95.
  • 17. Kimbrough RD and Gaines TB (1971). Hexachlorophene effects on the rat brain. Study of high doses by light and electron microscopy. Arch. Environ. Health 23: 114–118.[Web of Science][Medline] [Order article via Infotrieve]
  • 18. Lippert B, Metcalf BW, Jung MJ, and Casara P (1977). 4-Amino-hex-5-enoic-acid, a selective catalytic inhibitor of 4-aminobutyric acid aminotrans-ferase in mammalian brain. Eur. J. Biochem. 74: 441–445.[Web of Science][Medline] [Order article via Infotrieve]
  • 19. Lippert BJ, Haegele KD, Olberding EL, Hurst GH, Heeg JF, and Schechter PJ. Unpublished pharma-cokinetic data. Merrell Dow Research Institute, Cincinnati, Ohio.
  • 20. Loiseau P, Pardenberg JP, Pestre M, Guyot M, Schechter PJ, and Tell GP (1986). Double-blind pla-cebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy. Epilepsia 27: 115–120.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 21. Meldrum M and Horton R (1987). Blockade of epileptic responses in the photosensitive baboon, Papio papio, by two irreversible inhibitors of GABA trans-aminase, {gamma}-acetylenic GABA (4-amino-hex-5-enoic acid) and {gamma}-vinyl GABA (4-amino-hex-5-enoic acid). Psychopharmacology 59: 47–50.[CrossRef]
  • 22. Myslobodsky MS, Ackerman RF, and Engel J Jr, (1979). Effects of {gamma}-vinyl GABA on metrazol-acti-vated, and kindled seizures. Pharmacol. Biochem. Behav. 11: 265–71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 23. Palfreyman MG, Schechter PJ, Buckett WR, Tell GP, and Koch-Weser J (1981). The pharmacology of GABA-transaminase inhibitors. Biochem. Pharmacol. 30: 817–824, Errata 2385–2387.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 24. Pedersen B, Hojgaard K, and Dam M (1987). Vigabatrin: No microvacuoles in a human brain. Epilepsy Res. 1: 74–76.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 25. Perry TL, Kish SJ, and Hansen S (1979). Gamma-vinyl GABA: Effects of chronic administration on the metabolism of GABA and other amino compounds in rat brain. J. Neurochem. 32: 1641–1645.[Web of Science][Medline] [Order article via Infotrieve]
  • 26. Rimmer EM and Richens A (1984). Double-blind study of {gamma}-vinyl GABA in patients with refractory epilepsy. Lancet 1: 189–190.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 27. Saletu B, Brunberger J, Linzmayer L, Schwartz JJ, Haegele KD, and Schechter PJ (1986). Psychophysiological and psychometric studies after manipulating the GABA system by vigabatrin, a GABA-transaminase inhibitor, Internat. J. Psychophysiol. 4: 63–80.[CrossRef]
  • 28. Schechter PJ (1986). Vigabatrin. In: New Anliconvulsant Drugs, BS Meldrum and RJ Porter (eds). John Libbey and Co. Ltd., London, pp. 265–275.
  • 29. Schechter PJ, Tranier Y, Jung MJ, and Bohlen P (1977). Audiogenic seizure protection by elevated brain GABA concentration in mice: Effects of {gamma}-acetylenic GABA and {gamma}-vinyl GABA, two irreversible GABA-T inhibitors. Eur. J. Pharmacol. 45: 319–328.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 30. Schechter PJ, Lewis PJ, and Newbeme JW (1984). Gamma-vinyl GABA and GABA and beta-alanine transamination. Lancet 1: 737–738.[Web of Science][Medline] [Order article via Infotrieve]
  • 31. Tassinari CA, Michelucci R, Ambrosetto G, and Sal-vi F (1987). Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy. Arch. Neurol. 44: 907–910.[Abstract/Free Full Text]
  • 32. Tartara A, Manni R, Galimberti CA, Hardenberg J, Orwin J, and Perucca E (1986). Vigabatrin in the treatment of epilepsy: A double-blind placebo-controlled study. Epilepsia 27: 717–723.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 33. Towfighi J, Gontas NK, and McCree L (1974). Hcxa-chlorophene-induced changes in central and peripheral myelinated axons of developing and adult rats. Lab. Invest. 31:712–721.[Web of Science][Medline] [Order article via Infotrieve]
  • 34. Tucker WE and Howard JL. Wellcome Research Laboratories, Research Triangle Park, NC 27709. (Personal communication.)
  • 35. Weisse I, Stotzer H, Knappen F, and Walland A (1971). The effect of clonidine on the pupil diameter and the retina in rats, assessed in relation to the intensity of light. Arzneim. Forsch (Drug Res.) 21: 821–825.
  • 36. Yarrington JT, Sprinkle DJ, Loudy DE, Kariya T, and Gibson JP (1981). Effect of the hypolipidemic drug RMI 14,514 on hepatic ultrastructure of rats. Exp. Mol. Pathol. 34: 307–322.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 37. Yarrington JT and Gibson JP. Merrell Dow Research Institute, Cincinnati, OH 45215. (Unpublished toxicology data.)

Toxicologic Pathology, Vol. 18, No. 2, 225-238 (1990)
DOI: 10.1177/019262339001800201
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Toxicol PatholHome page
J. T. Yarrington, J. P. Gibson, J. E. Dillberger, G. Hurst, B. Lippert, N. M. Sussman, W. E. Heydorn, and R. J. Marler
Sequential Neuropathology of Dogs Treated with Vigabatrin, a GABA-Transaminase Inhibitor
Toxicol Pathol, September 1, 1993; 21(5): 480 - 489.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
J. Mumford and O. Dulac
Vigabatrin: A New Antiepileptic Medication
J Child Neurol, October 1, 1991; 6(2_suppl): 2S3 - 2S6.
[PDF]

Home page
 J Child NeurolHome page
D.J. Cannon, W.H. Butler, J.P. Mumford, and P.J. Lewis
Neuropathologic Findings in Patients Receiving Long-Term Vigabatrin Therapy for Chronic Intractable Epilepsy
J Child Neurol, October 1, 1991; 6(2_suppl): 2S17 - 2S24.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Gibson, J. P.
Right arrow Articles by Newberne, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gibson, J. P.
Right arrow Articles by Newberne, J. W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?